Promising lymphoma combo trial pulled before it began
NCT ID NCT04285268
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial was designed to test a combination of rituximab, venetoclax, and bortezomib in patients with diffuse large B-cell lymphoma that had come back or stopped responding to treatment. The goal was to see how many patients would have their tumors shrink or disappear. However, the study was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab, venetoclax, and bortezomib
What this could lead to
If this combination worked, it could offer a new treatment option for patients whose lymphoma has returned or not responded to standard therapy.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. The combination may have side effects like low blood counts or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States